FOREMOST Study Finds Oral Otezla® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early…
